Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Chronic Heart Failure

Free Subscription Articles published in Eur Heart J Retrieve available abstracts of 156 articles: HTML format Text format

Single Articles

April 2019
1. TRIPOSKIADIS F, Butler J, Abboud FM, Armstrong PW, et al
   The continuous heart failure spectrum: moving beyond an ejection fraction classification.
   Eur Heart J. 2019 Apr 8. pii: 5431175. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   February 2019
2. CLELAND JGF, van Veldhuisen DJ, Ponikowski P
   The year in cardiology 2018: heart failure.
   Eur Heart J. 2019;40:651-661.
   PubMed     Text format    
   
   
   
3. VAN DEN BERG MP, Mulder BA, Klaassen SHC, Maass AH, et al
   Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis.
   Eur Heart J. 2019 Feb 8. pii: 5310346. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   
4. HILFIKER-KLEINER D, Ardehali H, Fischmeister R, Burridge P, et al
   Late onset heart failure after childhood chemotherapy.
   Eur Heart J. 2019 Feb 7. pii: 5309990. doi: 10.1093.
   PubMed     Text format    
   
   
   
5. 
   Heart Failure and Sepsis: Cardiologists have developed a new 'risk profile' tool to identify heart failure patients at risk of dying from sepsis. Mark Nicholls reports.
   Eur Heart J. 2019;40:409-410.
   PubMed     Text format    
   
   
   January 2019
6. TARAMASSO M, Gavazzoni M, Maisano F
   Is tricuspid regurgitation a prognostic interventional target or is it just an indicator of worst prognosis in heart failure patients?
   Eur Heart J. 2019 Jan 25. pii: 5301478. doi: 10.1093.
   PubMed     Text format    
   
   
   
7. GORTER TM, van Veldhuisen DJ, Voors AA
   Rapid right-sided deterioration in heart failure with preserved ejection fraction.
   Eur Heart J. 2019 Jan 4. pii: 5273477. doi: 10.1093.
   PubMed     Text format    
   
   
   December 2018
8. HALLIDAY BP, Pennell DJ
   Prediction and prevention of heart failure in high-risk elderly patients.
   Eur Heart J. 2018 Dec 27. pii: 5263767. doi: 10.1093.
   PubMed     Text format    
   
   
   
9. LUSCHER TF
   Personalized approaches to heart failure: age, acute presentation, and comorbidities.
   Eur Heart J. 2018;39:4223-4226.
   PubMed     Text format    
   
   
   
10. RICHTER S, Di Biase L, Hindricks G
    Atrial fibrillation ablation in heart failure.
    Eur Heart J. 2018 Dec 14. pii: 5248225. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
11. TROMP J, Ouwerkerk W, Demissei BG, Anker SD, et al
    Novel endotypes in heart failure: effects on guideline-directed medical therapy.
    Eur Heart J. 2018 Dec 13. pii: 5245844. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
12. OBOKATA M, Reddy YNV, Melenovsky V, Pislaru S, et al
    Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction.
    Eur Heart J. 2018 Dec 12. pii: 5240922. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    November 2018
13. TINI G, Olivotto I, Canepa M
    Letter regarding the article 'Heart failure with preserved ejection fraction: from mechanisms to therapies' by Lam and colleagues.
    Eur Heart J. 2018 Nov 29. pii: 5219619. doi: 10.1093.
    PubMed     Text format    
    
    
    
14. 
    Corrigendum to: Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF.
    Eur Heart J. 2018 Nov 23. pii: 5203433. doi: 10.1093.
    PubMed     Text format    
    
    
    
15. 
    Corrigendum to: Heart failure with preserved ejection fraction: from mechanisms to therapies.
    Eur Heart J. 2018 Nov 23. pii: 5203434. doi: 10.1093.
    PubMed     Text format    
    
    
    
16. SIONTIS KC, Yao X, Noseworthy PA
    Atrial fibrillation in heart failure syndromes: does it matter more in some than in others?
    Eur Heart J. 2018 Nov 20. pii: 5193438. doi: 10.1093.
    PubMed     Text format    
    
    
    
17. NISHIMURA M, Maisel AS
    Biomarkers: a window into the pathophysiology of atrial fibrillation in heart failure with reduced vs. preserved ejection fraction.
    Eur Heart J. 2018;39:3876-3878.
    PubMed     Text format    
    
    
    October 2018
18. BOERSMA LVA
    Biventricular pacing after AV-node ablation for atrial fibrillation with heart failure: something old and something new, future standard, or just for the few?
    Eur Heart J. 2018 Oct 25. pii: 5145027. doi: 10.1093.
    PubMed     Text format    
    
    
    
19. BEGGS SAS, Jhund PS, McMurray JJV
    Anticoagulation, atherothrombosis, and heart failure: lessons from COMMANDER-HF and CORONA.
    Eur Heart J. 2018 Oct 23. pii: 5143981. doi: 10.1093.
    PubMed     Text format    
    
    
    
20. SAVARESE G, Dahlstrom U, Vasko P, Pitt B, et al
    Association between renin-angiotensin system inhibitor use and mortality/morbidity in elderly patients with heart failure with reduced ejection fraction: a prospective propensity score-matched cohort study.
    Eur Heart J. 2018 Oct 22. pii: 5142410. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
21. WANG N, Fulcher J, Abeysuriya N, McGrady M, et al
    Tricuspid regurgitation is associated with increased mortality independent of pulmonary pressures and right heart failure: a systematic review and meta-analysis.
    Eur Heart J. 2018 Oct 22. pii: 5142409. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
22. FUDIM M, Ganesh A, Green C, Jones WS, et al
    Splanchnic nerve block for decompensated chronic heart failure: splanchnic-HF.
    Eur Heart J. 2018 Oct 20. pii: 5135328. doi: 10.1093.
    PubMed     Text format    
    
    
    
23. YANG XQ, Xiong T, Wang DX
    The potential multiple effects of beta3-adrenergic receptor agonists on the heart protection for patients with heart failure with preserved ejection fraction.
    Eur Heart J. 2018 Oct 17. pii: 5137111. doi: 10.1093.
    PubMed     Text format    
    
    
    
24. BALLIGAND JL
    Response to 'The potential multiple effects of beta3-adrenergic receptor agonists on the heart protection for patients with heart failure with preserved ejection fraction'.
    Eur Heart J. 2018 Oct 17. pii: 5137137. doi: 10.1093.
    PubMed     Text format    
    
    
    
25. ZAFRIR B, Lund LH, Laroche C, Ruschitzka F, et al
    Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry.
    Eur Heart J. 2018 Oct 15. pii: 5133012. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
26. MAACK C, Lehrke M, Backs J, Heinzel FR, et al
    Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology.
    Eur Heart J. 2018 Oct 8. pii: 5123540. doi: 10.1093.
    PubMed     Text format    
    
    
    
27. HASIN T, Glikson M, Hasin Y
    The Heart Failure Unit At Shaare Zedek Hospital Medical Center.
    Eur Heart J. 2018;39:3491-3492.
    PubMed     Text format    
    
    
    
28. HASIN T, Zalut T, Hasin Y
    Managing the Patient with Heart Failure in the Emergency Department.
    Eur Heart J. 2018;39:3493-3495.
    PubMed     Text format    
    
    
    September 2018
29. ESHAK N, Abdelnaby M, Shehata H, Ziada K, et al
    A case of fibrosing mediastinitis complicated by pulmonary hypertension and right-sided heart failure.
    Eur Heart J. 2018 Sep 7. pii: 5092489. doi: 10.1093.
    PubMed     Text format    
    
    
    August 2018
30. SHAH SJ, Lam CSP, Svedlund S, Saraste A, et al
    Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF.
    Eur Heart J. 2018 Aug 27. pii: 5077831. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
31. GUSTAFSSON F, Shaw S, Lavee J, Saeed D, et al
    Six-month outcomes after treatment of advanced heart failure with a full magnetically levitated continuous flow left ventricular assist device: report from the ELEVATE registry.
    Eur Heart J. 2018 Aug 27. pii: 5084900. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
32. WEI J, Nelson MD, Sharif B, Shufelt C, et al
    Why do we care about coronary microvascular dysfunction and heart failure with preserved ejection fraction: addressing knowledge gaps for evidence-based guidelines.
    Eur Heart J. 2018 Aug 27. pii: 5079249. doi: 10.1093.
    PubMed     Text format    
    
    
    
33. SANTEMA BT, Kloosterman M, Van Gelder IC, Mordi I, et al
    Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction.
    Eur Heart J. 2018 Aug 22. pii: 5077588. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
34. CHAGGAR P, Squire I, Kalra PR
    British Society of Heart Failure.
    Eur Heart J. 2018;39:2773-2774.
    PubMed     Text format    
    
    
    
35. LUSCHER TF
    Heart failure with preserved ejection fraction: unravelling an enigma.
    Eur Heart J. 2018;39:2763-2766.
    PubMed     Text format    
    
    
    
36. AMSTEIN R
    The New Postgraduate Course in Heart Failure.
    Eur Heart J. 2018;39:2775-2777.
    PubMed     Text format    
    
    
    
37. RUSH CJ, Campbell RT, Jhund PS, Petrie MC, et al
    Association is not causation: treatment effects cannot be estimated from observational data in heart failure.
    Eur Heart J. 2018 Aug 1. pii: 5063542. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    July 2018
38. TAKAHAMA H, Minamino N, Izumi C
    Plasma soluble neprilysin levels are unchanged during recovery after decompensation of heart failure: a matter of the magnitude of the changes in systemic haemodynamics?
    Eur Heart J. 2018 Jul 27. pii: 5060561. doi: 10.1093.
    PubMed     Text format    
    
    
    
39. VAN EMPEL V, Brunner-La Rocca HP
    Helping to understand heart failure with preserved ejection fraction.
    Eur Heart J. 2018 Jul 9. pii: 5050878. doi: 10.1093.
    PubMed     Text format    
    
    
    June 2018
40. GORTER TM, Obokata M, Reddy YNV, Melenovsky V, et al
    Exercise unmasks distinct pathophysiologic features in heart failure with preserved ejection fraction and pulmonary vascular disease.
    Eur Heart J. 2018 Jun 26. pii: 5045545. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
41. WEBER T, Chirinos JA
    Pulsatile arterial haemodynamics in heart failure.
    Eur Heart J. 2018 Jun 26. pii: 5045547. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
42. PACKER M
    Questioning the obvious: does dyspnoea really matter in heart failure?
    Eur Heart J. 2018 Jun 22. pii: 5043114. doi: 10.1093.
    PubMed     Text format    
    
    
    
43. LAM CSP, Voors AA, de Boer RA, Solomon SD, et al
    Heart failure with preserved ejection fraction: from mechanisms to therapies.
    Eur Heart J. 2018 Jun 13. pii: 5037246. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    May 2018
44. LUSCHER TF
    Mechanisms and outcomes of heart failure: from HFpEF, HFmrEF, and HFrEF to transplantation.
    Eur Heart J. 2018;39:1749-1753.
    PubMed     Text format    
    
    
    
45. ANGERMANN CE, Frantz S, Maack C
    The Comprehensive Heart Failure Centre in Wurzburg, Germany.
    Eur Heart J. 2018;39:1757-1760.
    PubMed     Text format    
    
    
    
46. SWOBODA PP, Plein S
    Heart failure in Diabetic patients.
    Eur Heart J. 2018;39:1755-1757.
    PubMed     Text format    
    
    
    
47. OBOKATA M, Olson TP, Reddy YNV, Melenovsky V, et al
    Haemodynamics, dyspnoea, and pulmonary reserve in heart failure with preserved ejection fraction.
    Eur Heart J. 2018 May 19. pii: 4999864. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    March 2018
48. VADUGANATHAN M, Solomon SD
    Expanding the global borders of heart failure: the SHOP and PEOPLE studies.
    Eur Heart J. 2018 Mar 22. pii: 4951580. doi: 10.1093.
    PubMed     Text format    
    
    
    
49. FONSECA C
    A Heart Failure Clinic.
    Eur Heart J. 2018;39:826-828.
    PubMed     Text format    
    
    
    
50. BEGGS S, Gardner R
    Thirty years of heart failure.
    Eur Heart J. 2018;39:824-826.
    PubMed     Text format    
    
    
    February 2018
51. EL HARANE N, Kervadec A, Bellamy V, Pidial L, et al
    Acellular therapeutic approach for heart failure: in vitro production of extracellular vesicles from human cardiovascular progenitors.
    Eur Heart J. 2018 Feb 6. pii: 4840711. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    January 2018
52. LAM CSP, Gamble GD, Ling LH, Sim D, et al
    Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study.
    Eur Heart J. 2018 Jan 29. pii: 4829677. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
53. NELSON MD, Wei J, Bairey Merz CN
    Coronary microvascular dysfunction and heart failure with preserved ejection fraction as female-pattern cardiovascular disease: the chicken or the egg?
    Eur Heart J. 2018 Jan 16. pii: 4811982. doi: 10.1093.
    PubMed     Text format    
    
    
    
54. HEINZMANN D, Seizer P
    Mitochondria in heart failure: EMID-sign.
    Eur Heart J. 2018 Jan 3. pii: 4786075. doi: 10.1093.
    PubMed     Text format    
    
    
    
55. LUND LH, Kober L, Swedberg K, Ruschitzka F, et al
    The year in cardiology 2017: heart failure.
    Eur Heart J. 2018 Jan 2. pii: 4774532. doi: 10.1093.
    PubMed     Text format    
    
    
    
56. LUSCHER TF
    Heart failure subgroups: HFrEF, HFmrEF, and HFpEF with or without mitral regurgitation.
    Eur Heart J. 2018;39:1-4.
    PubMed     Text format    
    
    
    
57. PACKER M
    The Future Treatment of Heart Failure?
    Eur Heart J. 2018;39:5-7.
    PubMed     Text format    
    
    
    December 2017
58. TAQUETI VR, Solomon SD, Shah AM, Desai AS, et al
    Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction.
    Eur Heart J. 2017 Dec 26. pii: 4775060. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
59. ARRIGO M, Vodovar N, Nougue H, Sadoune M, et al
    The heart regulates the endocrine response to heart failure: cardiac contribution to circulating neprilysin.
    Eur Heart J. 2017 Dec 13. pii: 4735305. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
60. WILCOX JE, Mann DL
    Beta-blockers for the treatment of heart failure with a mid-range ejection fraction: deja-vu all over again?
    Eur Heart J. 2017 Dec 11. pii: 4728646. doi: 10.1093.
    PubMed     Text format    
    
    
    November 2017
61. MASIP J, Peacock WF, Price S, Cullen L, et al
    Indications and practical approach to non-invasive ventilation in acute heart failure.
    Eur Heart J. 2017 Nov 26. pii: 4654494. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
62. GRASSI G, Mancia G
    'Keep an eye' on the heart: retinal microcirculation disarray in congestive heart failure.
    Eur Heart J. 2017 Nov 23. pii: 4654727. doi: 10.1093.
    PubMed     Text format    
    
    
    
63. NICHOLLS M
    Finn Waagstein MD PhD: Finn Waagstein reflects on his work and research which saw beta-blockers revolutionise the treatment of heart failure patients. Mark Nicholls reports.
    Eur Heart J. 2017;38:3249-3250.
    PubMed     Text format    
    
    
    
64. ROSANO GMC
    HFA Congress 2017: The Congress of the Heart Failure Association of the ESC: a continuous success story, the result of a long-term vision.
    Eur Heart J. 2017;38:3042-3043.
    PubMed     Text format    
    
    
    
65. TOFIELD A
    Heart Failure Congress sets record: The 2017 ESC Heart Failure Association Congress had a new record number of submissions for original science.
    Eur Heart J. 2017;38:3041.
    PubMed     Text format    
    
    
    October 2017
66. NAGELE MP, Barthelmes J, Ludovici V, Cantatore S, et al
    Retinal microvascular dysfunction in heart failure.
    Eur Heart J. 2017 Oct 21. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
67. CLELAND JGF, Bunting KV, Flather MD, Altman DG, et al
    Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials.
    Eur Heart J. 2017 Oct 10. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
68. LUSCHER TF
    Special issues in heart failure: pulmonary hypertension, deranged potassium levels, and haemodynamic profiles.
    Eur Heart J. 2017;38:2857-2859.
    PubMed     Text format    
    
    
    
69. BLANTON RM
    What can haemodynamic profiles teach us about heart failure in the paediatric population?
    Eur Heart J. 2017;38:2910-2911.
    PubMed     Text format    
    
    
    
70. PITT B, Rossignol P
    Serum potassium in patients with chronic heart failure: once we make a U-turn where should we go?
    Eur Heart J. 2017;38:2897-2899.
    PubMed     Text format    
    
    
    
71. CHEN S, Dykes JC, McElhinney DB, Gajarski RJ, et al
    Haemodynamic profiles of children with end-stage heart failure.
    Eur Heart J. 2017;38:2900-2909.
    PubMed     Text format     Abstract available
    
    
    
72. ALDAHL M, Jensen AC, Davidsen L, Eriksen MA, et al
    Associations of serum potassium levels with mortality in chronic heart failure patients.
    Eur Heart J. 2017;38:2890-2896.
    PubMed     Text format     Abstract available
    
    
    September 2017
73. SCHMIEDER RE, Wagner F, Mayr M, Delles C, et al
    The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study.
    Eur Heart J. 2017 Sep 27. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    August 2017
74. SZUMMER K, Wallentin L, Lindhagen L, Alfredsson J, et al
    Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995-2014.
    Eur Heart J. 2017 Aug 29. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
75. FITCHETT D, Butler J, van de Borne P, Zinman B, et al
    Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME(R) trial.
    Eur Heart J. 2017 Aug 28. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
76. LUSCHER TF
    Update on heart failure: biomarkers, intensive therapy, remote monitoring, and cardiomyocyte renewal.
    Eur Heart J. 2017;38:2315-2317.
    PubMed     Text format    
    
    
    
77. DE BOER RA, Meems LMG, van Veldhuisen DJ
    Vitamin D supplementation in heart failure: case closed?
    Eur Heart J. 2017;38:2287-2289.
    PubMed     Text format    
    
    
    July 2017
78. DE WAHA S, Patel MR, Granger CB, Ohman EM, et al
    Relationship between microvascular obstruction and adverse events following primary primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an individual patient data pooled analysis from seven randomized trials.
    Eur Heart J. 2017 Jul 28. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
79. GOLIASCH G, Bartko PE, Pavo N, Neuhold S, et al
    Refining the prognostic impact of functional mitral regurgitation in chronic heart failure.
    Eur Heart J. 2017 Jul 25. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    June 2017
80. LUSCHER TF
    Risk factors for chronic heart failure: obesity, renal dysfunction, arteriovenous fistulas, and amyloid deposition.
    Eur Heart J. 2017;38:1857-1860.
    PubMed     Text format    
    
    
    
81. ROURA S, Galvez-Monton C, Lupon J, Bayes-Genis A, et al
    Biotherapies and biomarkers for cardiovascular diseases: A 15-year journey at the ICREC (Heart Failure and Cardiac Regeneration) Research Laboratory in Barcelona, Spain.
    Eur Heart J. 2017;38:1784-1786.
    PubMed     Text format    
    
    
    
82. CHATTERJEE NA, Singh JP
    Making sense of remote monitoring studies in heart failure.
    Eur Heart J. 2017 Jun 13. doi: 10.1093.
    PubMed     Text format    
    
    
    
83. SUGIHARA S, Burnett JC Jr
    BLAST-AHF: insights into biased AT1 ligands and heart failure. Beginning of the end or end of the beginning?
    Eur Heart J. 2017 Jun 1. doi: 10.1093.
    PubMed     Text format    
    
    
    May 2017
84. MORGAN JM, Kitt S, Gill J, McComb JM, et al
    Remote management of heart failure using implantable electronic devices.
    Eur Heart J. 2017 May 27. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
85. SCUFFHAM PA, Ball J, Horowitz JD, Wong C, et al
    Standard vs. intensified management of heart failure to reduce healthcare costs: results of a multicentre, randomized controlled trial.
    Eur Heart J. 2017 May 20. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
86. ZITTERMANN A, Ernst JB, Prokop S, Fuchs U, et al
    Effect of vitamin D on all-cause mortality in heart failure (EVITA): a 3-year randomized clinical trial with 4000 IU vitamin D daily.
    Eur Heart J. 2017 May 12. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
87. SCHUPKE S, Mehilli J
    Less myocardial scar but greater propensity for heart failure: another gender paradox in myocardial infarction.
    Eur Heart J. 2017 May 5. doi: 10.1093.
    PubMed     Text format    
    
    
    April 2017
88. PANG PS, Butler J, Collins SP, Cotter G, et al
    Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF).
    Eur Heart J. 2017 Apr 27. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
89. BORLAUG BA, Obokata M
    Is it time to recognize a new phenotype? Heart failure with preserved ejection fraction with pulmonary vascular disease.
    Eur Heart J. 2017 Apr 17. doi: 10.1093.
    PubMed     Text format    
    
    
    
90. LUSCHER TF
    From systemic and pulmonary hypertension to heart failure: novel drugs and devices.
    Eur Heart J. 2017;38:1087-1090.
    PubMed     Text format    
    
    
    
91. CLELAND JGF, Mueller C
    What can we learn from SOCRATES: more questions than answers?
    Eur Heart J. 2017;38:1128-1131.
    PubMed     Text format    
    
    
    
92. MCDIARMID AK, Pellicori P, Cleland JG, Plein S, et al
    Taxonomy of segmental myocardial systolic dysfunction.
    Eur Heart J. 2017;38:942-954.
    PubMed     Text format     Abstract available
    
    
    March 2017
93. PIESKE B, Maggioni AP, Lam CS, Pieske-Kraigher E, et al
    Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study.
    Eur Heart J. 2017 Mar 22. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
94. MCCULLOUGH PA, Rios A, Smith B
    Dialysis fistulas and heart failure.
    Eur Heart J. 2017 Mar 17. doi: 10.1093.
    PubMed     Text format    
    
    
    
95. OUWERKERK W, Voors AA, Anker SD, Cleland JG, et al
    Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study.
    Eur Heart J. 2017 Mar 11. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
96. LUSCHER TF
    Frontiers in heart failure: sodium, longitudinal strain, contractility sensor, fatal arrhythmias, and stroke.
    Eur Heart J. 2017;38:693-696.
    PubMed     Text format    
    
    
    
97. ABDUL-RAHIM AH, Perez AC, MacIsaac RL, Jhund PS, et al
    Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials.
    Eur Heart J. 2017;38:742-750.
    PubMed     Text format     Abstract available
    
    
    
98. BAX JJ, Delgado V, Sogaard P, Singh JP, et al
    Prognostic implications of left ventricular global longitudinal strain in heart failure patients with narrow QRS complex treated with cardiac resynchronization therapy: a subanalysis of the randomized EchoCRT trial.
    Eur Heart J. 2017;38:720-726.
    PubMed     Text format     Abstract available
    
    
    
99. STEPHAN VON BARDELEBEN R, Tamm A, Emrich T, Munzel T, et al
    Percutaneous transvenous direct annuloplasty of a human tricuspid valve using the Valtech Cardioband.
    Eur Heart J. 2017;38:690.
    PubMed     Text format    
    
    
    February 2017
100. 
     Corrigendum to: Sacubitril/valsartan and low blood pressure in heart failure with reduced ejection fraction [Eur Heart J 2017; doi:10.1093/eurheartj/ehx014].
     Eur Heart J. 2017 Feb 28. doi: 10.1093.
     PubMed     Text format    
     
     
     
101. MULLENS W, Verbrugge FH, Nijst P, Tang WH, et al
     Renal sodium avidity in heart failure: from pathophysiology to treatment strategies.
     Eur Heart J. 2017 Feb 23. doi: 10.1093.
     PubMed     Text format     Abstract available
     
     
     
102. MATHUR A, Fernandez-Aviles F, Dimmeler S, Hauskeller C, et al
     The consensus of the Task Force of the European Society of Cardiology concerning the clinical investigation of the use of autologous adult stem cells for the treatment of acute myocardial infarction and heart failure: update 2016.
     Eur Heart J. 2017 Feb 15. doi: 10.1093.
     PubMed     Text format    
     
     
     
103. BAYES-GENIS A, Voors AA, Zannad F, Januzzi JL, et al
     Transitioning from usual care to biomarker-based personalized and precision medicine in heart failure: call for action.
     Eur Heart J. 2017 Feb 15. doi: 10.1093.
     PubMed     Text format    
     
     
     
104. BOHM M, Young R, Jhund PS, Solomon SD, et al
     Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.
     Eur Heart J. 2017 Feb 1. doi: 10.1093.
     PubMed     Text format    
     
     
     
105. SINGH A, Laribi S, Teerlink JR, Mebazaa A, et al
     Agents with vasodilator properties in acute heart failure.
     Eur Heart J. 2017;38:317-325.
     PubMed     Text format    
     
     
     
106. LUSCHER TF
     An update on heart failure: from experimental findings to clinical trials.
     Eur Heart J. 2017;38:305-307.
     PubMed     Text format    
     
     
     
107. TOFIELD A
     Teenage weight and risk for adult heart failure.
     Eur Heart J. 2017;38:311-312.
     PubMed     Text format    
     
     
     
108. TOFIELD A
     End of the road for aliskiren in heart failure.
     Eur Heart J. 2017;38:312-313.
     PubMed     Text format    
     
     
     
109. 
     Professor Jay Cohn a pioneer in heart failure.
     Eur Heart J. 2017;38:308-309.
     PubMed     Text format    
     
     
     
110. HARPER AR, Cowie MR
     Remote monitoring for heart failure: the story moves on.
     Eur Heart J. 2017;38:310-311.
     PubMed     Text format    
     
     
     January 2017
111. BRUNO RM, Taddei S
     Sacubril/valsartan and low blood pressure in heart failure with reduced ejection fraction.
     Eur Heart J. 2017 Jan 30. doi: 10.1093.
     PubMed     Text format    
     
     
     
112. HORCKMANS M, Ring L, Duchene J, Santovito D, et al
     Neutrophils orchestrate post-myocardial infarction healing by polarizing macrophages towards a reparative phenotype.
     Eur Heart J. 2017;38:187-197.
     PubMed     Text format    
     
     
     
113. LANDIN AM, Hare JM
     The quest for a successful cell-based therapeutic approach for heart failure.
     Eur Heart J. 2017 Jan 10. pii: ehw626. doi: 10.1093.
     PubMed     Text format    
     
     
     
114. BAVENDIEK U, Aguirre Davila L, Koch A, Bauersachs J, et al
     Assumption versus evidence: the case of digoxin in atrial fibrillation and heart failure.
     Eur Heart J. 2017 Jan 8. pii: ehw577. doi: 10.1093.
     PubMed     Text format    
     
     
     
115. CHATTERJEE NA, Borgquist R, Chang Y, Lewey J, et al
     Increasing sex differences in the use of cardiac resynchronization therapy with or without implantable cardioverter-defibrillator.
     Eur Heart J. 2017 Jan 8. pii: ehw598. doi: 10.1093.
     PubMed     Text format     Abstract available
     
     
     
116. MAGGIONI AP, Ruschitzka F
     The year in cardiology 2016: heart failure.
     Eur Heart J. 2017 Jan 2. pii: ehw638. doi: 10.1093.
     PubMed     Text format    
     
     
     December 2016
117. MAISEL AS, Di Somma S
     Do we need another heart failure biomarker: focus on soluble suppression of tumorigenicity 2 (sST2).
     Eur Heart J. 2016 Dec 27. pii: ehw462. doi: 10.1093.
     PubMed     Text format    
     
     
     
118. NAKAMURA T, Masumoto A, Tahara N, Kuroda Y, et al
     Acute heart failure caused by mechanical valve leaflet dislodgment at the mitral position.
     Eur Heart J. 2016 Dec 23. pii: ehw521. doi: 10.1093.
     PubMed     Text format    
     
     
     
119. BARTUNEK J, Terzic A, Davison BA, Filippatos GS, et al
     Cardiopoietic cell therapy for advanced ischemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial.
     Eur Heart J. 2016 Dec 23. pii: ehw543. doi: 10.1093.
     PubMed     Text format     Abstract available
     
     
     
120. HOEPER MM, Lam CS, Vachiery JL, Bauersachs J, et al
     Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further researchdagger.
     Eur Heart J. 2016 Dec 23. pii: ehw597. doi: 10.1093.
     PubMed     Text format    
     
     
     
121. MINOIA C, Paolillo S
     Two weeks at Harvard, for two European heart failure trainees.
     Eur Heart J. 2016;37:3553-3554.
     PubMed     Text format    
     
     
     
122. PAOLILLO S
     The ESC Heart Failure Association postgraduate course in heart failure.
     Eur Heart J. 2016;37:3551-3552.
     PubMed     Text format    
     
     
     November 2016
123. AMMIRATI E, Burns JC, Moreo A, Daniels LB, et al
     Extreme giant aneurysms of three coronary arteries causing heart failure as late sequelae of Kawasaki disease.
     Eur Heart J. 2016.
     PubMed     Text format    
     
     
     
124. 
     What the Heart Failure Congress means to the Heart Failure Association.
     Eur Heart J. 2016;37:3124-3126.
     PubMed     Text format    
     
     
     
125. 
     First European advice launched for acute heart failure.
     Eur Heart J. 2016;37:3123-3124.
     PubMed     Text format    
     
     
     
126. 
     What's new in the European Society of Cardiology 2016 Guidelines for the diagnosis and treatment of acute and chronic heart failure?
     Eur Heart J. 2016;37:3121-3122.
     PubMed     Text format    
     
     
     October 2016
127. CREA F, Bairey Merz CN, Beltrame JF, Kaski JC, et al
     The parallel tales of microvascular angina and heart failure with preserved ejection fraction: a paradigm shift.
     Eur Heart J. 2016.
     PubMed     Text format    
     
     
     
128. DOCHERTY KF, Campbell RT, Jhund PS, Petrie MC, et al
     How robust are clinical trials in heart failure?
     Eur Heart J. 2016.
     PubMed     Text format     Abstract available
     
     
     September 2016
129. JORGE C, Hiltrop N, Desmet W
     Heart failure with preserved ejection fraction: blame the veins....
     Eur Heart J. 2016.
     PubMed     Text format    
     
     
     
130. MOHSENI H, Kiran A, Khorshidi R, Rahimi K, et al
     Influenza vaccination and risk of hospitalization in patients with heart failure: a self-controlled case series study.
     Eur Heart J. 2016.
     PubMed     Text format     Abstract available
     
     
     
131. JHUND PS
     Obesity and heart failure: when 'epidemics' collide.
     Eur Heart J. 2016 Sep 22. doi: 10.1093.
     PubMed     Text format    
     
     
     
132. FRADLEY MG
     The evolving field of cardio-oncology: beyond anthracyclines and heart failure.
     Eur Heart J. 2016;37:2740-2742.
     PubMed     Text format    
     
     
     
133. ZHABYEYEV P, Oudit GY
     Unravelling the molecular basis for cardiac iron metabolism and deficiency in heart failure.
     Eur Heart J. 2016.
     PubMed     Text format    
     
     
     
134. KOYAMA M, Yano T, Kikuchi K, Nagahara D, et al
     Lethal heart failure with anti-mitochondrial antibody: an arrhythmogenic right ventricular cardiomyopathy mimetic.
     Eur Heart J. 2016.
     PubMed     Text format    
     
     
     
135. 
     The Acute Heart Failure Academy.
     Eur Heart J. 2016;37:2568-9.
     PubMed     Text format    
     
     
     
136. LUSCHER TF
     From heart failure to transplantation: genes, miRNAs, and biomarkers.
     Eur Heart J. 2016;37:2561-3.
     PubMed     Text format    
     
     
     August 2016
137. LUSCHER TF
     Atrial fibrillation and stroke: risk factors, anticoagulation, and left atrial appendage occluders.
     Eur Heart J. 2016;37:2443-5.
     PubMed     Text format    
     
     
     April 2016
138. SMISETH OA, Torp H, Opdahl A, Haugaa KH, et al
     Myocardial strain imaging: how useful is it in clinical decision making?
     Eur Heart J. 2016;37:1196-207.
     PubMed     Text format     Abstract available
     
     
     
139. PATIL NP, Weymann A, Popov AF, Simon AR, et al
     Chest X-ray in cardiac illness: a tale of four decades.
     Eur Heart J. 2016;37:1243.
     PubMed     Text format    
     
     
     
140. SCHMIDT M, Lamberts M, Olsen AM, Fosboll E, et al
     Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology.
     Eur Heart J. 2016;37:1015-23.
     PubMed     Text format    
     
     
     March 2016
141. LUSCHER TF
     Update on hypertension: target blood pressure, comorbidities, and outcome.
     Eur Heart J. 2016;37:921-3.
     PubMed     Text format    
     
     
     February 2016
142. LOCH A, Geh DJ, Veriah RS
     Cardiac magnetic resonance imaging: a tool to diagnose parasitic infection?
     Eur Heart J. 2016;37:702.
     PubMed     Text format    
     
     
     
143. DWECK M, Chin C
     CardioPulse: Settling scores with a failing heart.
     Eur Heart J. 2016;37:433-4.
     PubMed     Text format    
     
     
     
144. WESTENBRINK BD, van Laake LW, Brugts JJ
     CardioPulse: The Postgraduate Course in Heart Failure.
     Eur Heart J. 2016;37:428-9.
     PubMed     Text format    
     
     
     
145. DIMARCO A, Mansoubi H, Tanner M
     An unusual cause of left ventricular hypertrophy.
     Eur Heart J. 2016;37:497.
     PubMed     Text format    
     
     
     
146. LECLERCQ C, Sadoul N, Mont L, Defaye P, et al
     Comparison of right ventricular septal pacing and right ventricular apical pacing in patients receiving cardiac resynchronization therapy defibrillators: the SEPTAL CRT Study.
     Eur Heart J. 2016;37:473-83.
     PubMed     Text format     Abstract available
     
     
     
147. STONE GW, Chung ES, Stancak B, Svendsen JH, et al
     Peri-infarct zone pacing to prevent adverse left ventricular remodelling in patients with large myocardial infarction.
     Eur Heart J. 2016;37:484-93.
     PubMed     Text format     Abstract available
     
     
     January 2016
148. RABER L, Piccolo R
     CardioPulse: Different bleeding scores and which one should we use?
     Eur Heart J. 2016;37:327-31.
     PubMed     Text format    
     
     
     
149. NICHOLLS M
     CardioPulse: Cyclosporine to reduce myocardial infarction injury?
     Eur Heart J. 2016;37:210-1.
     PubMed     Text format    
     
     
     December 2015
150. IUNG B, Doco-Lecompte T, Chocron S, Strady C, et al
     Cardiac surgery during the acute phase of infective endocarditis: discrepancies between European Society of Cardiology guidelines and practices.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     November 2015
151. PULS M, Lubos E, Boekstegers P, von Bardeleben RS, et al
     One-year outcomes and predictors of mortality after MitraClip therapy in contemporary clinical practice: results from the German transcatheter mitral valve interventions registry.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     August 2015
152. MALASA M, Werner N, Nickenig G, Hammerstingl C, et al
     Transcatheter tricuspid valve repair in a patient with isolated functional tricuspid valve regurgitation.
     Eur Heart J. 2015.
     PubMed     Text format    
     
     
     
153. CHATTERJEE NA, Roka A, Lubitz SA, Gold MR, et al
     Reduced appropriate implantable cardioverter-defibrillator therapy after cardiac resynchronization therapy-induced left ventricular function recovery: a meta-analysis and systematic review.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     July 2015
154. CORRADO D, Wichter T, Link MS, Hauer R, et al
     Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement.
     Eur Heart J. 2015.
     PubMed     Text format    
     
     
     June 2015
155. YSSAP J, Lebreton G, Hoen B, Larifla L, et al
     Infected left ventricular thrombus revealing an unrecognized coronary dissection after blunt chest trauma, treated with emergency heart transplantation.
     Eur Heart J. 2015.
     PubMed     Text format    
     
     
     
156. FANKHAUSER CD, Nietlispach F, Emmert MY, Maisano F, et al
     Antegrade valve embolization after transcatheter treatment for pure aortic regurgitation.
     Eur Heart J. 2015.
     PubMed     Text format    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Chronic Heart Failure is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: